AstraZeneca Spends $800m On Amolyt And Awaits A Readout
The Phase III trial of hypoparathyroidism asset eneboparatide will have to hit if AstraZeneca is going to carve out market share from Ascendis.
The Phase III trial of hypoparathyroidism asset eneboparatide will have to hit if AstraZeneca is going to carve out market share from Ascendis.